Study Reveals Treatment Gap
More than half of patients with metastatic lung cancer do not receive life-extending treatments such as chemotherapy, immunotherapy, and targeted therapy, according to a new study published Thursday in JAMA Oncology. This finding highlights a significant gap in cancer care.
The study analyzed over 250,000 Medicare beneficiaries between 2006 and 2021, with an average age of 73. Researchers found that the proportion of patients receiving these treatments increased from 45% to 48% over time, yet still remained below half.
Barriers to Care
For some patients, a pill can hold the disease in check for years, yet many never receive such therapies. Delays in follow-up imaging, biopsy, and appointments after a suspicious scan may contribute to the low treatment rates observed.
Patients and healthcare providers should be aware of these findings. It is important to consult a healthcare professional to discuss appropriate treatment options for metastatic lung cancer. The study underscores the need for improved access to care.
Frequently Asked Questions
What percentage of patients with metastatic lung cancer do not receive life-extending treatments?
More than half (over 50%) of patients with metastatic lung cancer do not receive life-extending treatments like chemotherapy, immunotherapy, and targeted therapy.
How did the treatment rate for metastatic lung cancer change between 2006 and 2021?
The proportion of patients who received these treatments increased from 45% to 48% over that period.
What was the average age of patients in the study published in JAMA Oncology?
The study analyzed over 250,000 Medicare patients with an average age of 73.
